1. Home
  2. PRQR vs PIM Comparison

PRQR vs PIM Comparison

Compare PRQR & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRQR
  • PIM
  • Stock Information
  • Founded
  • PRQR 2012
  • PIM 1988
  • Country
  • PRQR Netherlands
  • PIM United States
  • Employees
  • PRQR N/A
  • PIM N/A
  • Industry
  • PRQR Biotechnology: Pharmaceutical Preparations
  • PIM Finance Companies
  • Sector
  • PRQR Health Care
  • PIM Finance
  • Exchange
  • PRQR Nasdaq
  • PIM Nasdaq
  • Market Cap
  • PRQR 179.1M
  • PIM 161.4M
  • IPO Year
  • PRQR 2014
  • PIM N/A
  • Fundamental
  • Price
  • PRQR $2.30
  • PIM $3.35
  • Analyst Decision
  • PRQR Strong Buy
  • PIM
  • Analyst Count
  • PRQR 8
  • PIM 0
  • Target Price
  • PRQR $8.88
  • PIM N/A
  • AVG Volume (30 Days)
  • PRQR 356.8K
  • PIM 57.5K
  • Earning Date
  • PRQR 08-07-2025
  • PIM 01-01-0001
  • Dividend Yield
  • PRQR N/A
  • PIM 8.28%
  • EPS Growth
  • PRQR N/A
  • PIM N/A
  • EPS
  • PRQR N/A
  • PIM 0.05
  • Revenue
  • PRQR $21,212,711.00
  • PIM N/A
  • Revenue This Year
  • PRQR N/A
  • PIM N/A
  • Revenue Next Year
  • PRQR N/A
  • PIM N/A
  • P/E Ratio
  • PRQR N/A
  • PIM $63.80
  • Revenue Growth
  • PRQR 85.91
  • PIM N/A
  • 52 Week Low
  • PRQR $1.07
  • PIM $2.90
  • 52 Week High
  • PRQR $4.62
  • PIM $3.28
  • Technical
  • Relative Strength Index (RSI)
  • PRQR 68.07
  • PIM 54.39
  • Support Level
  • PRQR $2.10
  • PIM $3.34
  • Resistance Level
  • PRQR $2.18
  • PIM $3.35
  • Average True Range (ATR)
  • PRQR 0.13
  • PIM 0.03
  • MACD
  • PRQR 0.01
  • PIM 0.00
  • Stochastic Oscillator
  • PRQR 54.55
  • PIM 72.73

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

About PIM Putnam Master Intermediate Income Trust

Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.

Share on Social Networks: